Biotech Stocks Facing FDA Decision In June

The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts.

from RTT - Biotech http://ift.tt/24el0Bm
via IFTTT